CoChat

Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology

Open access
Huang, Shichao, Zhang, Zhen, Cao, Junwei, Yu, Yongchun, Pei, Gang · 2022 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The apolipoprotein E4 ( APOE4 ) genotype is one of the strongest genetic risk factors for Alzheimer’s disease (AD), and is generally believed to cause widespread pathological alterations in various types of brain cells. Here, we developed a novel engineering method of creating the chimeric human cerebral organoids (chCOs) to assess the differential roles of APOE4 in neurons and astrocytes. First, the astrogenic factors NFIB and SOX9 were introduced into induced pluripotent stem cells (iPSCs) to accelerate the induction of astrocytes. Then the above induced iPSCs were mixed and cocultured with noninfected iPSCs under the standard culturing condition of cerebral organoids. As anticipated, the functional astrocytes were detected as early as 45 days, and it helped more neurons matured in chCOs in comparation of the control human cerebral organoids (hCOs). More interestingly, this method enabled us to generate chCOs containing neurons and astrocytes with different genotypes, namely APOE3 or APOE4 . Then, it was found in chCOs that astrocytic APOE4 already significantly promoted lipid droplet formation and cholesterol accumulation in neurons while both astrocytic and neuronal APOE4 contributed to the maximum effect. Most notably, we observed that the co-occurrence of astrocytic and neuronal APOE4 were required to elevate neuronal phosphorylated tau levels in chCOs while Aβ levels were increased in chCOs with neuronal APOE4 . Altogether, our results not only revealed the essence of both neuronal and astrocytic APOE4 for tau pathology, but also suggested chCOs as a valuable pathological model for AD research and drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-01006-x

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Induction of astrocytes in human cerebral organoids by Sox9 and NFIB expression. a Experiment procedure for generation of chCOs and control hCOs. b, c Immunostaining of chCOs and control hCOs on D20 for GFAP. Shown in c is the quantification of the percentage of the GFAP-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 5 organoids, from three different batches; **p < 0.01). Scale bars in b: 50 µm. d, e Immunostaining of chCOs and control hCOs on D45 for GFAP. Shown in e is the quantification of the percentage of the GFAP-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; **p < 0.01). Scale bars in d: left image 100 µm, right image 30 µm for hCOs and chCOs, respectively. f, g Immunostaining of chCOs and control hCOs on D45 for S100B. Shown in g is the quantification of the percentage of the S100B-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 8 organoids, from three different batches; **p < 0.01). h Flow cytometry analysis of CD44 expression of chCO and control hCO cells. i Immunostaining of astrocyte-lineage cells purified from chCOs on D45 for GFAP and S100B. Scale bars, 20 µm. j qPCR analysis of mature and fetal astrocyte gene expression of chCO and control hCO cells. Data represent the mean ± s.e.m. (n = 5 different batches; *p < 0.05, **p < 0.01)
Fig. 1 Induction of astrocytes in human cerebral organoids by Sox9 and NFIB expression. a Experiment procedure for generation of chCOs and control hCOs. b, c Immunostaining of chCOs and control hCOs on D20 for GFAP. Shown in c is the quantification of the percentage of the GFAP-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 5 organoids, from three different batches; **p < 0.01). Scale bars in b: 50 µm. d, e Immunostaining of chCOs and control hCOs on D45 for GFAP. Shown in e is the quantification of the percentage of the GFAP-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; **p < 0.01). Scale bars in d: left image 100 µm, right image 30 µm for hCOs and chCOs, respectively. f, g Immunostaining of chCOs and control hCOs on D45 for S100B. Shown in g is the quantification of the percentage of the S100B-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 8 organoids, from three different batches; **p < 0.01). h Flow cytometry analysis of CD44 expression of chCO and control hCO cells. i Immunostaining of astrocyte-lineage cells purified from chCOs on D45 for GFAP and S100B. Scale bars, 20 µm. j qPCR analysis of mature and fetal astrocyte gene expression of chCO and control hCO cells. Data represent the mean ± s.e.m. (n = 5 different batches; *p < 0.05, **p < 0.01)CC BY · PubMed Central
Fig. 2 Functional analysis of induced astrocytes in human brain organoids. a Glutamate uptake by astrocyte purified from D45 chCOs. Data represent the mean ± s.e.m. (n = 4 different batches; ***p < 0.001). b, c Immunostaining of chCOs and control hCOs on D20 for EdU and DCX. Shown in c is the quantification of the density of the EdU/DCX-double-positive cells. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; *p < 0.05). Scale bar in a: 50 µm. d, e Immunostaining of chCOs and control hCOs on D30 and D45 for MAP2. Shown in e is the quantification of the percentage of the MAP2-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 6–8 organoids, from three different batches; **p < 0.01, **p < 0.001). Scale bars in d: upper panel 100 µm, lower panel 20 µm (D20); upper panel 100 µm, lower panel 50 µm (D45); f, g Immunostaining of chCOs and control hCOs on D60 for synaptophysin (SYN) and PSD95. Shown in g is the quantification of the density of the SYN or PSD95-positive puncta over the whole organoid area. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; *p < 0.05). Scale bars in e: left panel 20 µm, right panel 10 µm. h, i Immunostaining of chCOs and control hCOs on D45 for cleaved caspase-3. Shown in i is the quantification of the density of the cleaved caspase-3-positive cells. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; **p < 0.01). Scale bars in g: 50 µm. j Current clamp recordings of one cell in chCOs and control hCOs on D60. k Action potential (AP) of chCOs and control hCOs on D60. l Total Aβ levels in the supernatants of chCOs and control hCOs on D20 and D30. Data represent the mean ± s.e.m. (n = 3 different batches; ***p < 0.001)
Fig. 2 Functional analysis of induced astrocytes in human brain organoids. a Glutamate uptake by astrocyte purified from D45 chCOs. Data represent the mean ± s.e.m. (n = 4 different batches; ***p < 0.001). b, c Immunostaining of chCOs and control hCOs on D20 for EdU and DCX. Shown in c is the quantification of the density of the EdU/DCX-double-positive cells. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; *p < 0.05). Scale bar in a: 50 µm. d, e Immunostaining of chCOs and control hCOs on D30 and D45 for MAP2. Shown in e is the quantification of the percentage of the MAP2-positive area over the whole organoid area. Data represent the mean ± s.e.m. (n = 6–8 organoids, from three different batches; **p < 0.01, **p < 0.001). Scale bars in d: upper panel 100 µm, lower panel 20 µm (D20); upper panel 100 µm, lower panel 50 µm (D45); f, g Immunostaining of chCOs and control hCOs on D60 for synaptophysin (SYN) and PSD95. Shown in g is the quantification of the density of the SYN or PSD95-positive puncta over the whole organoid area. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; *p < 0.05). Scale bars in e: left panel 20 µm, right panel 10 µm. h, i Immunostaining of chCOs and control hCOs on D45 for cleaved caspase-3. Shown in i is the quantification of the density of the cleaved caspase-3-positive cells. Data represent the mean ± s.e.m. (n = 7 organoids, from three different batches; **p < 0.01). Scale bars in g: 50 µm. j Current clamp recordings of one cell in chCOs and control hCOs on D60. k Action potential (AP) of chCOs and control hCOs on D60. l Total Aβ levels in the supernatants of chCOs and control hCOs on D20 and D30. Data represent the mean ± s.e.m. (n = 3 different batches; ***p < 0.001)CC BY · PubMed Central
Fig. 3 Astrocytic and neuronal APOE4 elevated cholesterol and lipid droplet levels in neurons. a Experiment procedure for generation of chCOs with neurons and astrocytes carrying APOE3 or APOE4 allele. b Representative images of different chCOs on D45 stained with filipin, MAP2, and human nuclei. Scale bar: 50 µm. c Quantification of mean filipin fluorescence density in the neurons. Data represent the mean ± s.e.m. (n = 6–8 organoids, from three different batches; ***p < 0.001). d Representative images of chCOs and control hCOs on D45 stained with LipidTox and MAP2. Scale bar: 30 µm. e Quantification of the lipid droplet density in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from four different batches; *p < 0.05, ***p < 0.001)
Fig. 3 Astrocytic and neuronal APOE4 elevated cholesterol and lipid droplet levels in neurons. a Experiment procedure for generation of chCOs with neurons and astrocytes carrying APOE3 or APOE4 allele. b Representative images of different chCOs on D45 stained with filipin, MAP2, and human nuclei. Scale bar: 50 µm. c Quantification of mean filipin fluorescence density in the neurons. Data represent the mean ± s.e.m. (n = 6–8 organoids, from three different batches; ***p < 0.001). d Representative images of chCOs and control hCOs on D45 stained with LipidTox and MAP2. Scale bar: 30 µm. e Quantification of the lipid droplet density in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from four different batches; *p < 0.05, ***p < 0.001)CC BY · PubMed Central
Fig. 4 The co-occurrence of APOE4 astrocytes and neurons are required for the elevation of neuronal p-tau levels. a Aβ40 levels in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; ***p < 0.001). b Aβ42 levels in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; ***p < 0.001). c The ratio of Aβ42/ Aβ40 in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; **p < 0.01). d qPCR analysis of Aβ depredating enzymes expression in different chCOs. Data represent the mean ± s.e.m. (n = 5 different batches; **p < 0.01, ***p < 0.001). e Immunostaining of different chCOs on D45 for p-tau (AT8) and MAP2. Scale bar: 50 µm. f Quantification of the p-tau (AT8) intensity in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; ***p < 0.001). g The percentage of the p-tau (AT8)-positive area in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; **p < 0.01, ***p < 0.001). h Immunostaining of different chCOs on D45 for p-tau (PHF1) and TUJ1. Scale bar: 30 µm. i Quantification of the p-tau (PHF1) intensity in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; *p < 0.05, **p < 0.01, ***p < 0.001). j The percentage of the p-tau (PHF1)-positive area in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; **p < 0.01, ***p < 0.001). k p-tau (PHF1) levels of different chCOs on D45 analyzed by western blotting. l Quantification of p-tau (PHF1) levels normalized to total tau. Data represent the mean ± s.e.m. (n = 3 different batches). m chCOs were analyzed for p-tau (AT8) and MAP2 after 10-day-treatment of simvastatin (10 µM) and atorvastatin (10 µM) (D35-D45). Scale bar: 30 µm. n Quantification of the p-tau (AT8) intensity in the neurons of chCOs from m. Data represent the mean ± s.e.m. (n = 6 organoids, from three different batches; ***p < 0.001, compared with NE4 + AE4 vehicle group). o Current clamp recordings of one cell in different chCOs on D60. p Action potential (AP) of different chCOs on D60
Fig. 4 The co-occurrence of APOE4 astrocytes and neurons are required for the elevation of neuronal p-tau levels. a Aβ40 levels in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; ***p < 0.001). b Aβ42 levels in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; ***p < 0.001). c The ratio of Aβ42/ Aβ40 in the supernatants of different chCOs on D45. Data represent the mean ± s.e.m. (n = 6 different batches; **p < 0.01). d qPCR analysis of Aβ depredating enzymes expression in different chCOs. Data represent the mean ± s.e.m. (n = 5 different batches; **p < 0.01, ***p < 0.001). e Immunostaining of different chCOs on D45 for p-tau (AT8) and MAP2. Scale bar: 50 µm. f Quantification of the p-tau (AT8) intensity in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; ***p < 0.001). g The percentage of the p-tau (AT8)-positive area in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; **p < 0.01, ***p < 0.001). h Immunostaining of different chCOs on D45 for p-tau (PHF1) and TUJ1. Scale bar: 30 µm. i Quantification of the p-tau (PHF1) intensity in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; *p < 0.05, **p < 0.01, ***p < 0.001). j The percentage of the p-tau (PHF1)-positive area in the neurons. Data represent the mean ± s.e.m. (n = 8–9 organoids, from three different batches; **p < 0.01, ***p < 0.001). k p-tau (PHF1) levels of different chCOs on D45 analyzed by western blotting. l Quantification of p-tau (PHF1) levels normalized to total tau. Data represent the mean ± s.e.m. (n = 3 different batches). m chCOs were analyzed for p-tau (AT8) and MAP2 after 10-day-treatment of simvastatin (10 µM) and atorvastatin (10 µM) (D35-D45). Scale bar: 30 µm. n Quantification of the p-tau (AT8) intensity in the neurons of chCOs from m. Data represent the mean ± s.e.m. (n = 6 organoids, from three different batches; ***p < 0.001, compared with NE4 + AE4 vehicle group). o Current clamp recordings of one cell in different chCOs on D60. p Action potential (AP) of different chCOs on D60CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 76

Metadata

Authors
Huang, S., Zhang, Z., Cao, J., Yu, Y., & Pei, G.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Tongji University (CN)
Corresponding author
  • Huang, Shichao
  • Pei, Gang
Venue
Signal Transduction and Targeted Therapy
Published
2022-06-13
Volume
7
Issue
1
Pages
176-176
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4282592266
Cited by
72
References
42
Citations by year
2026: 12 · 2025: 21 · 2024: 20 · 2023: 16 · 2022: 2
FWCI
9.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (81901094)
  • Chinese Academy of Sciences (2018YFA0108003, 81901094, XDA16010309)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
APOE ε4, Alzheimer's disease, tau pathology, astrocytes, neurons, induced pluripotent stem cells, NFIB, SOX9, lipid droplet formation, cholesterol accumulation, amyloid-beta
MeSH terms
Alzheimer Disease, Astrocytes, Humans, Neurons, Organoids, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology. https://app.cochat.ai/papers/10.1038/s41392-022-01006-x
The paper
Huang, S., Zhang, Z., Cao, J., Yu, Y., & Pei, G. (2022). Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-01006-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.